CYP2D6 and breast carcinoma: The CYP2D6*10 genotype is associated with lower levels of active metabolites of tamoxifen in Asian breast cancer patients, which may impact the clinical effectiveness of tamoxifen31, 32, 33 and had poor prognosis.9